Trial Profile

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Bone metastases; Liver metastases; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE641
Sponsors Merck Sharp & Dohme Corp.

20 Dec 2024 Planned End Date changed from 31 May 2024 to 29 May 2026.
24 Oct 2023 Results reporting safety and efficacy data presented at the 48th European Society for Medical Oncology Congress
13 Jun 2023 Planned End Date changed from 28 Dec 2023 to 31 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com